Vincent Sardi, MD
Retina Specialist · Langhorne, PANPI 1366411233
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 25.0% of the total. That places this record below the midpoint for retina specialist clinicians in PA, where the typical reported total is $2,388.
Across 50 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$234
- Regeneron Healthcare Solutions, Inc.$213
- Genentech USA, Inc.$174
- Apellis Pharmaceuticals, Inc.$94
- Astellas Pharma US Inc$85
- ANI Pharmaceuticals, Inc.$36
- plus $100 from 5 others
What the payments were for
- Food & beverage$92098%
- Education$162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $234 |
| Regeneron Healthcare Solutions, Inc. | 12 | $213 |
| Genentech USA, Inc. | 8 | $174 |
| Apellis Pharmaceuticals, Inc. | 4 | $94 |
| Astellas Pharma US Inc | 4 | $85 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Alimera Sciences, Inc. | 2 | $30 |
| Rxsight Inc | 1 | $19 |
| Amgen | 1 | $18 |
| Novartis | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
How this compares
$936 in reported general payments places this provider in the 25th percentile of 43 retina specialist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ofloxacin | 312 | $4,859 |
| Ciprofloxacin Hcl | 194 | $1,928 |
| Prednisolone Acetate | 27 | $1,408 |
| Ketorolac Tromethamine | 23 | $302 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Langhorne
- Joshua GreenePhiladelphia$394K
- Jay ChhablaniPittsburgh$70K
- Sachin PatelPottsville$17K
- Brian VanderbeekPhiladelphia$14K
- Thucanh MultererFogelsville$9K
- Christopher BairHermitage$9K
- Albert MaguirePhiladelphia$9K
- Hugo LinaresPhiladelphia$7K
- Moiz CarimWyomissing$6K
- Salman PorbandarwallaLancaster$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.